Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders

NCT02392559 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

158

Enrollment

INDUSTRY

Sponsor class

Conditions

Heterozygous Familial Hypercholesterolemia

Interventions

DRUG: Evolocumab
DRUG: Placebo

Sponsor

Amgen